Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation

Annals of the New York Academy of Sciences

Volumn 1188, Issue , 2010, Pages 78-86

  Antzelevitch, Charles ^a   Burashnikov, Alexander ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

Antiarrhythmic drugs; Arrhythmias; Electrophysiology; Pharmacology

Indexed keywords

AMIODARONE; ION CHANNEL; RANOLAZINE; SODIUM CHANNEL BLOCKING AGENT;

CONFERENCE PAPER; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE REMODELING; HUMAN; MUSCLE ACTION POTENTIAL; REPOLARIZATION;

EID: 77649121199     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05086.x     Document Type: Conference Paper

References (47)

1. Fuster, V., L. E. Ryden, D. S. Cannom, et al. 2006. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). J. Am. Coll. Cardiol. 48: 854-906. (Pubitemid 44175743) (Pubitemid 44175743)
2. Calkins, H., J. Brugada, D. L. Packer, et al. 2007. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 4: 816-861.
3. Nerbonne, J. M. & R. S. Kass. 2005. Molecular physiology of cardiac repolarization. Physiol. Rev. 85: 1205-1253.
4. Tamargo, J., R. Caballero, R. Gomez, et al. 2004. Pharmacology of cardiac potassium channels. Cardiovasc. Res. 62: 9-33.
5. Wijffels, M. C., C. J. Kirchhof, R. Dorland, et al. 1995. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 92: 1954-1968.
6. Nattel, S., B. Burstein & D. Dobrev. 2008. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ. Arrhythm. Electrophysiol. 1: 62-73. (Pubitemid 351260071) (Pubitemid 351260071)
7. Nattel, S. & L. Carlsson. 2006. Innovative approaches to anti-arrhythmic drug therapy. Nat. Rev. Drug Discov. 5: 1034-1049. (Pubitemid 44835130) (Pubitemid 44835130)
8. Kur): rationale, pharmacology and evidence for potential therapeutic value. J. Cardiovasc. Pharmacol. 52: 105-120.
9. Fedida, D. 2007. Vernakalant (RSD1235): a novel, atrialselective antifibrillatory agent. Expert Opin. Investig. Drugs 16: 519-532. (Pubitemid 46554469) (Pubitemid 46554469)
10. Carlsson, L., D. Chartier & S. Nattel. 2006. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J. Cardiovasc. Pharmacol. 47: 123-132. (Pubitemid 44378235) (Pubitemid 44378235)
11. Blaauw, Y., H. Gogelein, R. G. Tieleman, et al. 2004. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVEO118 in remodeled atria of the goat. Circulation 110: 1717-1724. (Pubitemid 39299211) (Pubitemid 39299211)
12. K,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br. J. Pharmacol. 154: 1619-1630.
13. Feng,J.,D.Xu,Z.Wang&S.Nattel.1998. Ultrarapiddelayedrectifiercurrentinactivationinhumanatrialmyocytes: propertiesandconsequences.Am.J.Physiol.275:H1717-H1725.(Pubitemid28543705)
14. + current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res. 80: 772-781.
15. Kur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 110: 2299-2306.
16. Kur promote atrial fibrillation? Heart Rhythm. 5: 1304-1309.
17. Ehrlich, J. R. & S. Nattel. 2009. Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope? Curr. Opin. Cardiol. 24: 50-55.
18. Burashnikov, A. & C. Antzelevitch. 2009. New pharmacological strategies for the treatment of atrial fibrillation. Ann. Noninvasive Electrocardiol. 14: 290-300.
19. Olson, T. M., A. E. Alekseev, X. K. Liu, et al. 2006. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum. Mol. Genet. 15: 2185-2191.
20. Burashnikov, A., J. M. Di Diego, A. C. Zygmunt, et al. 2007. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 116: 1449-1457.
21. Burashnikov, A., J. M. Di Diego, S. Sicouri, et al. 2008. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm. 5: 1735-1742.
22. Burashnikov, A., J. M. Di Diego, A. C. Zygmunt, et al. 2008. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation. Ann. N. Y. Acad. Sci. 1123: 105-112.
23. Burashnikov, A. & C. Antzelevitch. 2008. Atrial-selective sodium channel blockers: do they exist? J. Cardiovasc. Pharmacol. 52: 121-128.
24. Burashnikov, A., L. Belardinelli & C. Antzelevitch. 2007. Ranolazine and propafenone both suppress atrial fibrillation but ranolazine unlike propafenone does it without prominent effects on ventricular myocardium. Heart Rhythm. 4: S163. Abstract.
25. Antzelevitch, C., L. Belardinelli, A. C. Zygmunt, et al. 2004. Electrophysiologic effects of ranolazine: a novel anti-anginal agent with antiarrhythmic properties. Circulation 110: 904-910.
26. Kodama, I., K. Kamiya & J. Toyama. 1999. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am. J. Cardiol. 84: 20R-28R. (Pubitemid 29527987) (Pubitemid 29527987)
27. Singh, B. N. 2008. Amiodarone as paradigm for developing new drugs for atrial fibrillation. J. Cardiovasc Pharmacol. 52: 300-305.
28. Persson, F., L. Carlsson, G. Duker & I. Jacobson. 2005. Blocking characteristics of hERG, hNav1.5, and hKvLQTl/hminK after administration of an antiarrhythmic compound AZD7009. J. Cardiovasc. Electrophysiol. 16: 329-341. (Pubitemid 40404601) (Pubitemid 40404601)
29. Persson, F., L. Carlsson, G. Duker, et al. 2005. Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009. J. Cardiovasc Pharmacol. 46: 7-17.
30. Goldstein, R. N., C. Khrestian, L. Carlsson, et al. 2004. Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J. Cardiovasc. Electrophysiol. 15: 1444-1450.
31. Kur blockers 3- [ (dimethylamino)methyl] -6-methoxy-2methyl-4-phenylisoquinolin-l(2H)-one and 2-phenyl1,1-dipyridin-3-yl-2-pyrrolidin-l-yl-ethanol in dogs with underlying heart failure. J. Pharmacol. Exp. Ther. 324: 322-330.
32. Kur block. Am. J. Physiol. 286: H2393-H2400.
33. Courtemanche, M., R. J. Ramirez & S. Nattel. 1999. Ionic targets for drug therapy and atrial fibrillationinduced electrical remodeling: insights from a mathematical model. Cardiovasc. Res. 42: 477-489. (Pubitemid 29243173) (Pubitemid 29243173)
34. GolodDA,KumarR,JoynerRW.1998. Determinantsofactionpotentialinitiationinisolatedrabbitatrialand ventricularmyocytes.Am.J.Physiol.274:H1902-H1913.(Pubitemid28308808)
35. + current in single atrial and ventricular guinea-pig myocytes, by a new antiarrhythmic drug, Ro 22-9194. Fundam Clin. Pharmacol. 11: 402-1107
36. Li, G. R., C. P. Lau & A. Shrier. 2002. Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts. J. Mol. Cell. Cardiol. 34: 1185-1194.
37. Carmeliet, E. & K. Mubagwa. 1998. Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Prog. Biophys. Mol. Biol. 70:1-72. (Pubitemid 28425790) (Pubitemid 28425790)
38. Hondeghem, L. M. & B. G. Katzung. 1995. Mechanism of action of antiarrhythmic drugs. In Physiology and Pathophysiology of the Heart, 3rd edn. N. Sperelakis, Ed.: 589-603. Kluwer Academic Publishers. Dordrecht, the Netherlands.
39. Scirica, B. M., D. A. Morrow, H. Hod, et al. 2007. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI36) randomized controlled trial. Circulation 116: 1647-1652.
40. Murdock, D. K., N. Overton, M. Kersten, et al. 2008. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol. J. 8: 175-181.
41. Antzelevitch,C.,L.Belardinelli,L.Wu,etal.2004. Electrophysiologicpropertiesandantiarrhythmicactionsofanovelanti-anginalagent.J. Cardiovasc.Pharmacol.Therapeut.9(Suppl1):S65-S83.(Pubitemid39334836)
42. Maltsev, V. A., H. N. Sabbah & A. I. Undrovinas. 2001. Late sodium current is a novel target for amiodarone: studies in failing human myocardium. J. Mol. Cell Cardiol. 33: 923-932.
43. Furukawa, T., S. Koumi, Y Sakakibara, et al. 1995. An analysis of lidocaine block of sodium current in isolated human atrial and ventricular myocytes. J. Mol. Cell. Cardiol. 27: 831-846.
44. Langenfeld,H.,J.Weirich,C.Kohler,etal.1990. ComparativeanalysisoftheactionofclassIantiarrhythmicdrugs(lidocaine,quinidine, andprajmaline)inrabbitatrialandventricularmyocardium.J.CardiovascPharmacol15: 338-345.(Pubitemid20040594)
45. Ahmmed, G. U., I. Hisatome, Y. Kurata, et al. 2002. Analysis of moricizine block of sodium current in isolated guinea-pig atrial myocytes: atrioventricular difference of moricizine block. Vascul. Pharmacol. 38: 131-141.
46. Nemeth, M., L. Virag, O. Hala, et al. 1996. The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibers. Cardiovasc Res. 31: 246-248. (Pubitemid 26089960) (Pubitemid 26089960)
47. max) of action potential in guineapig cardiac muscles. J. Mol. Cell Cardiol. 19: 367-377.